Biosynex stock rebounds by nearly 10%
The share of the Alsatian diagnostic test manufacturer posts spectacular gains during trading, amid ongoing creditor voting on a restructuring plan covering more than 80 million euros in claims. The movement occurs against the backdrop of a safeguard procedure opened last autumn, which continues to weigh on the stock's annual trajectory.
A violent intraday rebound that rises back above all moving averages
The Biosynex stock gains 9.64% to €0.98 during trading, after briefly falling to €0.86, below the €0.88 support level, before rebounding sharply. This downward breach of support therefore did not hold: the price quickly recovered above this threshold, illustrating the magnitude of the day's movement. The stock's monthly volatility, at 31.53%, reflects a high risk profile consistent with the erratic dynamics observed during the session.
Regarding moving averages, the price is now established above all three reference levels: it exceeds the 20-day MA at €0.92 (spread of +6.30%), the 50-day MA at €0.91 (+7.47%) and the 200-day MA at €0.85 (+15.06%). The RSI at 41 remains in neutral territory, with no overbought signal, which leaves technical room for the move. The nearest resistance is located at €1.00, approximately 2% from the current price.
Ongoing financial restructuring, the underlying driver of stock volatility
The fundamental context remains highly tense. Biosynex has been in safeguard proceedings since late September 2025, and a creditor ballot on a restructuring plan covering €81.8 million in liabilities is currently open as of September 4, 2026. This vote is scheduled to close on September 24, maintaining uncertainty over the process outcome for several more weeks. On the human side, co-founder Thierry Paper left his positions as Delegated Chief Executive Officer and Director on August 31, 2026, ahead of the initially planned date.
These governance and restructuring elements fuel nervousness around the matter. Over one year, the stock is still down 17.82%, despite gains of 8.67% over the week and 5.16% over three months. The outcome of the creditor vote, expected on September 24, constitutes the next concrete benchmark for the stock's valuation.
